[A17-28] Pembrolizumab (non-small cell lung cancer) - Addendum to Commission A17-06
Last updated 04.08.2017
Commission awarded on 21.06.2017 by the Federal Joint Committee (G-BA).
First-line therapy in patients with metastasizing NSCLC with PD-L1 expressing tumours and without activating EGFR or ALK mutation
Unchanged hint of considerable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.